Loading…
Cogent Biosciences, Inc. is projected to rise to $47.55 by 2027, a +22% move from its current price of $38.87. COGT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $38.16 | $38.88 | $39.61 | +0.02% |
| Jul 14 | $37.87 | $38.88 | $39.92 | +0.03% |
| Jul 15 | $37.66 | $38.89 | $40.16 | +0.05% |
| Jul 16 | $37.48 | $38.90 | $40.37 | +0.07% |
| Jul 17 | $37.32 | $38.90 | $40.56 | +0.08% |
| Jul 18 | $37.18 | $38.91 | $40.72 | +0.10% |
| Jul 19 | $37.05 | $38.92 | $40.88 | +0.12% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $37.05 | $38.92 | $40.88 | +0.12% |
| Week 2 | $36.34 | $38.96 | $41.77 | +0.24% |
| Week 3 | $35.82 | $39.01 | $42.48 | +0.35% |
| Week 4 | $35.39 | $39.05 | $43.09 | +0.47% |
| Week 5 | $35.02 | $39.10 | $43.65 | +0.59% |
| Week 6 | $34.70 | $39.15 | $44.16 | +0.71% |
| Week 7 | $34.41 | $39.19 | $44.64 | +0.83% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cogent Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib.
Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
Cogent Biosciences, Inc. (COGT) trades at $38.74 per share, with a market cap of $6.62B, and is ranked 1124. The multi-year forecast envisions a rising price path, with the 2026 average at $38.74 and the 2030 average at $66.97, rising further to $392.11 by 2050.
The forecast also shows a sequence of higher maximum values across years, reaching $92.24 in 2030 and $653.47 by 2050. Return profiles grow over time, with ROIs of 72.9% by 2030 and 912.1% by 2050. Overall sentiment is bullish in the longer horizon, with earlier years showing neutral to bullish outlooks.
A major floor 29.7% below — a decisive break under it would weaken the trend.
The nearest floor, 20.2% below — buyers have tended to step in here.
The nearest ceiling, 4.2% above — a clean break opens room to run.
A major ceiling 19.1% above — clearing it would confirm fresh momentum.
Key COGT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of COGT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $39.76 | Sell | $39.48 | Sell |
| MA 10 | $39.15 | Sell | $38.87 | Buy |
| MA 20 | $36.97 | Buy | $37.53 | Buy |
| MA 50 | $35.09 | Buy | $36.07 | Buy |
| MA 100 | $35.85 | Buy | $35.12 | Buy |
| MA 200 | $32.89 | Buy | $31.37 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 62.16 | Neutral |
| Stoch RSI (14) | 0.02 | Buy |
| CCI (20) | 54.11 | Neutral |
| Williams %R (14) | -35.12 | Info |
| MACD (12,26,9) | 0.24 | Buy |
| ROC (12) | 7.05 | Buy |
| Bollinger %B (20,2) | 0.68 | Neutral |
| Stochastic %K (14) | 64.88 | Neutral |
| TRIX (15) | 0.56 | Buy |
| Awesome (5,34) | 4.42 | Buy |
| Ultimate (7,14,28) | 60.30 | Neutral |
| Momentum (10) | 0.86 | Buy |
| Aroon Osc (25) | 88.00 | Buy |
| Hull MA (9) | 40.23 | Sell |
| ADX (14) | 31.48 | Buy |
| ATR (14) | 0.62 | Info |
In the near term, the technical picture is bullish. RSI (14) sits at 70, indicating strength, while the 50-day simple moving average is $34.66 and the 200-day simple moving average is $31.82, both suggesting an uptrend. A key resistance level is at $38.74, with a support level at $31.02.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $31.02 | $38.87 | $50.05 | 0% | Neutral | |
| $38.94 | $47.55 | $60.70 | +22% | Bullish | |
| $43.82 | $54.51 | $71.47 | +40% | Bullish | |
| $45.06 | $56.92 | $76.22 | +46% | Bullish | |
| $51.27 | $65.63 | $89.47 | +69% | Bullish | |
| $61.06 | $79.12 | $109.56 | +104% | Bullish | |
| $70.12 | $91.89 | $129.04 | +136% | Bullish | |
| $81.09 | $107.39 | $152.77 | +176% | Bullish | |
| $84.54 | $113.07 | $162.77 | +191% | Bullish | |
| $88.27 | $119.18 | $173.47 | +207% | Bullish | |
| $142.50 | $200.67 | $306.09 | +416% | Bullish | |
| $245.51 | $370.79 | $606.28 | +854% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $31.02 | $38.87 | $46.02 | +0.00% |
| August 2026 | $32.99 | $38.63 | $46.20 | -0.63% |
| September 2026 | $33.55 | $39.47 | $47.58 | +2.18% |
| October 2026 | $34.23 | $40.42 | $49.05 | +2.42% |
| November 2026 | $34.00 | $40.30 | $49.17 | -0.31% |
| December 2026 | $34.32 | $40.81 | $50.05 | +1.27% |
Click any year to see its month-by-month COGT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect COGT to range from $31.02 to $50.05 through 2026. The $38.87 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The COGT price prediction for 2027 points to an average of $47.55 (low $38.94, high $60.70) — a potential gain of +22% on today's $38.87. Buyers look set to stay in control over this stretch.
In 2028, COGT is projected to trade between $43.82 and $71.47, averaging $54.51 — a potential gain of +40% from today's $38.87. That is up +15% on the projected 2027 average. Momentum favours further upside here.
Cogent Biosciences, Inc.'s 2029 outlook centres on $56.92, within a $45.06 to $76.22 range. That is up +4% on the projected 2028 average. That marks a +46% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, COGT could reach as high as $89.47, with a base case around $65.63 and support toward $51.27 — roughly +69% from $38.87. Momentum favours further upside here.
Expect COGT to range from $61.06 to $109.56 through 2031. The $79.12 average target implies a +104% move from current prices. That is up +21% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The COGT price prediction for 2032 points to an average of $91.89 (low $70.12, high $129.04) — a potential gain of +136% on today's $38.87. Momentum favours further upside here.
In 2033, COGT is projected to trade between $81.09 and $152.77, averaging $107.39 — a potential gain of +176% from today's $38.87. That is up +17% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Cogent Biosciences, Inc.'s 2034 outlook centres on $113.07, within a $84.54 to $162.77 range. That is up +5% on the projected 2033 average. That marks a +191% change versus current levels. Momentum favours further upside here.
By 2035, COGT could reach as high as $173.47, with a base case around $119.18 and support toward $88.27 — roughly +207% from $38.87. Buyers look set to stay in control over this stretch.
Expect COGT to range from $142.50 to $306.09 through 2040. The $200.67 average target implies a +416% move from current prices. That is up +68% on the projected 2035 average. Momentum favours further upside here.
The COGT price prediction for 2050 points to an average of $370.79 (low $245.51, high $606.28) — a potential gain of +854% on today's $38.87. Buyers look set to stay in control over this stretch.
Investing $1,000 in COGT today (≈ 25.726782 COGT) could be worth
$9,539.19
+$8,539.19 (+854%) by 2050 · US Dollar
Based on the average projected COGT price of $370.79 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in COGTwould be worth at today's price.
$1,000 invested in COGT on Jul 10, 2025 (≈ 92.165895 COGT) would be worth
$3,582.49
+$2,582.49 (+258.2%) today · 3.58× · US Dollar
Based on a COGT entry price of $10.85 vs. today's $38.87.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $38.69 | $1,004.65 | +0.5% |
| 1 month ago | $31.38 | $1,238.69 | +23.9% |
| 3 months ago | $36.37 | $1,068.74 | +6.9% |
| 6 months ago | $34.76 | $1,118.24 | +11.8% |
| 1 year ago | $10.85 | $3,582.49 | +258.2% |
| All time (5.0y) ago | $6.55 | $5,934.35 | +493.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our COGT forecast.
Our base-case forecast reaches $78.00 around 2031.
Implied market cap at $78.00: $13.33B
The year-by-year forecast shows a rising price trajectory from 2026 through 2050. In 2026, the average price is $38.74 (min $31.02, max $50.97). By 2027, the average rises to $48.00 (min $39.12, max $61.70) with a 23.9% ROI.
In 2028, the average is $54.55 (min $43.59, max $72.11) delivering a 40.8% ROI, and in 2029, the average is $58.13 (min $45.70, max $78.57) with a 50.1% ROI. By 2030, the average reaches $66.97 (min $51.90, max $92.24) and an ROI of 72.9%. The growth continues through 2031 ($80.85 avg, min $61.85, max $113.20, ROI 108.7%), 2032 ($94.92 avg, min $71.74, max $134.88, ROI 145%), and 2033 ($109.89 avg, min $82.13, max $158.29, ROI 183.7%).
The path extends to 2034 ($115.80 avg, min $85.62, max $168.88, ROI 198.9%) and 2035 ($123.76 avg, min $90.59, max $182.60, ROI 219.4%), then to 2040 ($206.64 avg, min $144.54, max $320.25, ROI 433.4%), and finally to 2050 ($392.11 avg, min $254.23, max $653.47, ROI 912.1%). The sentiment attached to these longer horizons is BULLISH, with the forecast suggesting meaningful upside over time, albeit with inherent uncertainty and volatility.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $66.97 with a min of $51.90 and a max of $92.24, and an ROI of 72.9%. The sentiment for 2030 is BULLISH.
Longer-term outlooks are bullish, with an average price of $392.11 by 2050 and an ROI of 912.1%. Note that 2026 is neutral, and the forecast includes year-by-year variability and inherent uncertainty.
Yes. The forecast for 2033 shows an average of $109.89 and a max of $158.29, indicating Cogent could exceed $100 in that year.
The 2040 forecast estimates an average price of $206.64 (min $144.54, max $320.25) with an ROI of 433.4%, and sentiment is BULLISH.
Current price is $38.74 per share, and market capitalization is $6.62B. The asset is ranked 1124.
Cogent Biosciences, Inc. Community Discussion
0Share your Cogent Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.